Gemcitabine

Biochem/physiol Actions Gemcitabine is a widely used antitumor agents in both clinics and research labs. It is an antineoplastic agent and antimetabolite.

GNE-900 is a an ATP-competitive, selective, and orally active ChK1 inhibitor with IC 50 s of 0.0011, 1.5 µM for ChKl, ChK2 , respectively. GNE-900 abrogates the G2-M checkpoint, enhances DNA damage, and induces Apoptosis . gemcitabine ( HY-17026 )

GNE-900 is a an ATP-competitive, selective, and orally active ChK1 inhibitor with IC 50 s of 0.0011, 1.5 µM for ChKl, ChK2 , respectively. GNE-900 abrogates the G2-M checkpoint, enhances DNA damage, and induces Apoptosis . gemcitabine ( HY-17026 )

GNE-900 is a an ATP-competitive, selective, and orally active ChK1 inhibitor with IC 50 s of 0.0011, 1.5 µM for ChKl, ChK2 , respectively. GNE-900 abrogates the G2-M checkpoint, enhances DNA damage, and induces Apoptosis . gemcitabine ( HY-17026 )

GNE-900 is a an ATP-competitive, selective, and orally active ChK1 inhibitor with IC 50 s of 0.0011, 1.5 µM for ChKl, ChK2 , respectively. GNE-900 abrogates the G2-M checkpoint, enhances DNA damage, and induces Apoptosis . gemcitabine ( HY-17026 )

Licoricidin (LCD) is isolated from Glycyrrhiza uralensis Fisch , possesses anti-cancer activities. Licoricidin (LCD) inhibit SW480 cells ( IC 50 =7.2 μM) by inducing cycle arrest, apoptosis and autophagy , and is a potential chemopreventive or

A DNA alkylating agents that induces DNA interstrand and intrastrand crosslinks, cytotoxicity, and apoptosis inhibits the growth of PC-3 prostate cancer cells with IC₅₀ values of 0.074 or 0.

Biochem/physiol Actions MGCD0103 (Mocetinostat) is an orally active, potent and subtype-selective histone deacetylase (HDAC) inhibitor (IC50: class I HDAC1/2/3 = 0.15/0.

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the

An orally available HDAC inhibitor that selectively targets HDAC1 and 2 (IC₅₀s = 0.15 and 0.

An orally available HDAC inhibitor that selectively targets HDAC1 and 2 (IC₅₀s = 0.15 and 0.

An orally available HDAC inhibitor that selectively targets HDAC1 and 2 (IC₅₀s = 0.15 and 0.